ADMA Biologics (NASDAQ:ADMA) Stock Price Up 5.6% - Time to Buy?

Key Points

• ADMA Biologics' stock price increased by 5.6% during trading on Friday, reaching a high of $18.23 before closing at $18.28.
• Equities research analysts have given mixed ratings, with Wall Street Zen downgrading the stock to "sell," while Raymond James Financial raised their target price and declared it a "strong-buy."
• The company reported quarterly earnings of $0.14 per share, which fell short of analyst expectations, despite a 40.2% year-over-year revenue increase.
• ADMA Biologics has a robust market capitalization of $4.33 billion and a current ratio indicating strong liquidity.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) shares shot up 5.6% during mid-day trading on Friday . The company traded as high as $18.23 and last traded at $18.28. 399,713 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 3,068,772 shares. The stock had previously closed at $17.31.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ADMA shares. Raymond James Financial increased their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th.

ADMA Biologics Stock Up 0.6%

The firm has a market cap of $4.32 billion, a PE ratio of 21.31 and a beta of 0.43. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. The firm's 50-day moving average price is $18.94 and its two-hundred day moving average price is $18.72.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The business's revenue was up 40.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.08 earnings per share. As a group, equities research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director directly owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. The trade was a 17.42% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director owned 478,194 shares in the company, valued at $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 464,621 shares of company stock valued at $9,644,269. 3.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock valued at $312,109,000 after acquiring an additional 80,302 shares during the last quarter. Invesco Ltd. increased its position in ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after purchasing an additional 1,570,649 shares in the last quarter. Geode Capital Management LLC increased its position in ADMA Biologics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock worth $93,187,000 after purchasing an additional 50,399 shares in the last quarter. Nuveen LLC acquired a new stake in ADMA Biologics during the 1st quarter worth approximately $93,543,000. Finally, Dimensional Fund Advisors LP increased its position in ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after purchasing an additional 643,661 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.